Dr. Reddy's Laboratories Ltd. (RDY)

35.20
0.04 0.11
NYSE : Health Technology
Prev Close 35.24
Open 35.39
Day Low/High 35.05 / 35.39
52 Wk Low/High 31.58 / 42.82
Volume 105.31K
Avg Volume 184.70K
Exchange NYSE
Shares Outstanding 166.06M
Market Cap 5.82B
EPS 1.60
P/E Ratio 21.49
Div & Yield 0.26 (0.82%)

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABEV, DGII, FLWS, JVA, LBRDA, MUR, OLP, RDY, SGEN, TESS, TWIN, VMC, YRCW Downgrades: CRUS, MINI, USLM, ZBH Initiations: CBTX, MBIN, SOGO Read on to get TheStreet Quant Ratings' detailed report:

Dr. Reddy's Q3 FY19 Financial Results

Dr. Reddy's Q3 FY19 Financial Results

Dr. Reddy's Laboratories Ltd.

Dr. Reddy's To Release Q3 FY19 Results On February 1, 2019

Dr. Reddy's To Release Q3 FY19 Results On February 1, 2019

Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will announce results for the quarter ended December 31, 2018 on Friday, February 1, 2019 after the Board Meeting.

Dr. Reddy's Laboratories Limited To Present At The 37th Annual J.P. Morgan Healthcare Conference

Dr. Reddy's Laboratories Limited To Present At The 37th Annual J.P. Morgan Healthcare Conference

Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced that the Company will be presenting at the 37th Annual J.

Dr. Reddy's Laboratories Launches Aspirin And Extended-Release Dipyridamole Capsules In The U.S. Market

Dr. Reddy's Laboratories Launches Aspirin And Extended-Release Dipyridamole Capsules In The U.S. Market

Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY), along with its subsidiaries together referred to as "Dr.

Dr. Reddy's Q2 & H1 FY19 Financial Results

Dr. Reddy's Q2 & H1 FY19 Financial Results

Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories Receives Approval For Aspirin And Extended-Release Dipyridamole Capsules In The U.S. Market

Dr. Reddy's Laboratories Receives Approval For Aspirin And Extended-Release Dipyridamole Capsules In The U.S. Market

Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr.

Dr. Reddy's To Release Q2 FY19 Results On October 26, 2018

Dr. Reddy's To Release Q2 FY19 Results On October 26, 2018

Dr. Reddy's Laboratories (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) will announce results for the quarter ended September 30, 2018 on Friday, October 26, 2018 after the Board Meeting.

Dr. Reddy's Q1 FY19 Financial Results

Dr. Reddy's Q1 FY19 Financial Results

Dr. Reddy's Laboratories Ltd.

Indivior Soars on Court Ruling Blocking Sales of Rival's Generic Opioid Drug

Indivior Soars on Court Ruling Blocking Sales of Rival's Generic Opioid Drug

The drug company received a preliminary injunction blocking Dr. Reddy's Laboratories from selling its opioid treatment drug.

Dr. Reddy's To Release Q1 FY19 Results On July 26, 2018

Dr. Reddy's To Release Q1 FY19 Results On July 26, 2018

Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will announce results for the quarter ended June 30, 2018 on Thursday, July 26, 2018 after the Board Meeting.

TheStreet Quant Rating: B- (Buy)